Prospective comparative study of long-term impact of radiofrequency ablation (RFA) versus stereotactic body radiotherapy (SBRT) on liver function in patients with single HCC

Prospective comparative study of long-term impact of radiofrequency ablation (RFA) versus stereotactic body radiotherapy (SBRT) on liver function in patients with single HCC - COMPASS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036081

Enrollment

150

Registered

2019-03-05

Start date

2019-03-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Single, 3cm or smaller, and no metastasis Life expectancy of 3 months or longer

Exclusion criteria

Exclusion criteria: Child-Pugh score of 10 or more Palliative radiotherapy Informed consent not obtained

Design outcomes

Primary

Measure	Time frame
Changes of ALBI score (comparison between baseline and 3 months after RFA/SBRT)	—

Secondary

Measure	Time frame
Local recurrence free survival Best treatment effect Recurrence Overall survival Changes of ALBI score (6, 9, and 12months) Changes of Child-Pugh score (3, 6, 9, and 12 months) Time to liver function worsening Adverse events	—

Countries

Japan

Contacts

Public ContactMasayuki Ueno

Kurashiki Central Hospital Department of Gastroenterology and Hepatology

mu13951@kchnet.or.jp0864220210

Outcome results